Effector Graham Number from 2010 to 2026
| EFTR Stock | USD 0.0006 0.0004 200.00% |
Graham Number | First Reported 2010-12-31 | Previous Quarter 43.66 | Current Value 31.23 | Quarterly Volatility 8.46132328 |
Check Effector Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Effector Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 104.8 K, Interest Expense of 2.1 M or Selling General Administrative of 10.1 M, as well as many indicators such as Price To Sales Ratio of 4.24, Dividend Yield of 0.0 or Days Sales Outstanding of 3.03. Effector financial statements analysis is a perfect complement when working with Effector Therapeutics Valuation or Volatility modules.
Effector | Graham Number | Build AI portfolio with Effector Stock |
Evaluating Effector Therapeutics's Graham Number across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Effector Therapeutics's fundamental strength.
Latest Effector Therapeutics' Graham Number Growth Pattern
Below is the plot of the Graham Number of Effector Therapeutics over the last few years. It is Effector Therapeutics' Graham Number historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Effector Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Graham Number | 10 Years Trend |
|
Graham Number |
| Timeline |
Effector Graham Number Regression Statistics
| Arithmetic Mean | 34.95 | |
| Geometric Mean | 34.10 | |
| Coefficient Of Variation | 24.21 | |
| Mean Deviation | 7.41 | |
| Median | 29.56 | |
| Standard Deviation | 8.46 | |
| Sample Variance | 71.59 | |
| Range | 18.9567 | |
| R-Value | 0.66 | |
| Mean Square Error | 42.79 | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | 1.11 | |
| Total Sum of Squares | 1,146 |
Effector Graham Number History
About Effector Therapeutics Financial Statements
Effector Therapeutics shareholders use historical fundamental indicators, such as Graham Number, to determine how well the company is positioned to perform in the future. Although Effector Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Effector Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Effector Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Graham Number | 43.66 | 31.23 |
Pair Trading with Effector Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Effector Stock Analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.